Arrowhead Pharmaceuticals: RNAi in the SpotlightArrowhead is at the forefront of RNAi therapies, and late-stage clinical results could lead to big pharma buyout interest. Biotech investors know the drill: success here could be worth a 70% move. MYNZ’s measured strategy in diagnostics ensures it remains a key name to watch in its own space.